Prelude Capital Management’s Heron Therapeutics HRTX Stock Holding History

Prelude Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,600	Closed	-$118K	–	1919
2022 Q1	$118K	Buy	+20,600	New	+$151K	﹤0.01%	1379
2020 Q3	–	Sell	-20,146	Closed	-$296K	–	2053
2020 Q2	$296K	Buy	+20,146	New	+$331K	0.02%	627
2020 Q1	–	Sell	-294	Closed	-$5.53K	–	1683
2019 Q4	$7K	Buy	+294	New	+$6.5K	﹤0.01%	1739
2019 Q3	–	Sell	-121	Closed	-$2K	–	1850
2019 Q2	$2K	Sell	121 -8,930	-99%	-$178K	﹤0.01%	1569
2019 Q1	$221K	Buy	+9,051	New	+$237K	0.01%	684
2018 Q4	–	Sell	-24,986	Closed	-$791K	–	1949
2018 Q3	$791K	Sell	24,986 -8,762	-26%	-$326K	0.05%	416
2018 Q2	$1.31M	Sell	33,748 -7,162	-18%	-$228K	0.08%	260
2018 Q1	$1.13M	Sell	40,910 -11,253	-22%	-$255K	0.08%	248
2017 Q4	$944K	Buy	52,163 +14,120	+37%	+$230K	0.08%	265
2017 Q3	$614K	Buy	+38,043	New	+$597K	0.06%	330
2016 Q2	–	Sell	-4,747	Closed	-$90K	–	1639
2016 Q1	$90K	Buy	+4,747	New	+$93.7K	0.01%	799
2015 Q4	–	Sell	-100	Closed	-$2K	–	1549
2015 Q3	$2K	Buy	+100	New	+$3.33K	﹤0.01%	1431
2014 Q3	–	Sell	-400	Closed	-$5K	–	1966
2014 Q2	$5K	Buy	+400	New	+$4.78K	﹤0.01%	1843

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Prelude Capital Management's HRTX Position: Q2 2022 in Review

Prelude Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 20,600 shares — an estimated $118K sold.

Prelude Capital Management first reported a position in HRTX in Q2 2014 and held it in 13 quarters. The position peaked at $1.31M in Q2 2018. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

Prelude Capital Management reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
Prelude Capital Management sold 20,600 Heron Therapeutics shares in Q2 2022, an estimated $118K.
Prelude Capital Management first reported a position in Heron Therapeutics in Q2 2014 and held it in 13 quarters.
Prelude Capital Management's Heron Therapeutics position peaked at $1.31M in Q2 2018.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.